BNP Paribas Financial Markets boosted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 29.3% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,380,229 shares of the financial services provider’s stock after purchasing an additional 538,899 shares during the period. BNP Paribas Financial Markets owned about 4.75% of iShares Biotechnology ETF worth $346,561,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IBB. Darwin Wealth Management LLC bought a new stake in iShares Biotechnology ETF in the third quarter worth approximately $29,000. Highline Wealth Partners LLC acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at $30,000. Bbjs Financial Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the 2nd quarter valued at $31,000. Ashton Thomas Securities LLC bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth about $36,000. Finally, Voisard Asset Management Group Inc. bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter worth about $59,000. 62.45% of the stock is owned by hedge funds and other institutional investors.
iShares Biotechnology ETF Stock Down 1.4 %
Shares of IBB traded down $1.92 during trading hours on Tuesday, hitting $137.99. The stock had a trading volume of 370,636 shares, compared to its average volume of 1,452,526. The company’s fifty day moving average is $143.27 and its two-hundred day moving average is $141.92. iShares Biotechnology ETF has a 52 week low of $117.28 and a 52 week high of $150.57.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- What is Insider Trading? What You Can Learn from Insider Trading
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- What is a Death Cross in Stocks?
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.